<DOC>
<DOCNO>
EP-0017477
</DOCNO>
<TEXT>
<DATE>
19801015
</DATE>
<IPC-CLASSIFICATIONS>
A61P-25/02 A61P-27/02 C07D-471/00 A61P-25/00 A61P-27/12 <main>C07D-471/20</main> A61K-31/55 C07D-455/00 C07D-471/20 A61P-3/08 A61P-27/00 C07D-215/22 A61P-3/00 C07D-455/04 C07D-215/227 A61K-31/47 C07D-215/00 A61P-3/10 
</IPC-CLASSIFICATIONS>
<TITLE>
spiro-quinolone hydantoins, pharmaceutical compositions containing them, and processes for their preparation.
</TITLE>
<APPLICANT>
pfizerus<sep>pfizer inc.<sep>pfizer inc.235 east 42nd streetnew york, n.y. 10017us<sep>pfizer inc.<sep>
</APPLICANT>
<INVENTOR>
schnur rodney caughren<sep>schnur, rodney caughren<sep>schnur, rodney caughren91 front streetnoank, new london connecticutus<sep>schnur, rodney caughren<sep>schnur, rodney caughren91 front streetnoank, new london connecticutus<sep>
</INVENTOR>
<ABSTRACT>
spiro-quinolone hydantoins having utility in preventing  or alleviating chronic diabetic complications such as catar­ acts, reinopathy and neuropathy of the formula:    and the pharmaceutically acceptable acid addition salts  thereof, wherein n is 1 or 2 and r₁ and r₂ are each hydrogen,  chloro, bromo, fluoro, c₁-c₃ alkyl or c₁-c₃ alkoxy; phar­ maceutical composition containing them, and processes for  their preparation.  
</ABSTRACT>
</TEXT>
</DOC>
